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Abstract
 .The multifunctional low density lipoprotein receptor-related proteinra -macroglobulin receptor LRP binds and2
 2q.degrades several ligands involved in protease and lipoprotein metabolism. We previously reported that nickel Ni
 ) .specifically inhibits the binding of activated a -macroglobulin a M at 48C to LRP and had no effect on the binding of2 2
  . .other ligands to the receptor Hussain et al. 1995 Biochem. 34, 16074–16081 . In the current investigation, we have
2q 125 )  .examined the effect of Ni on the catabolism of I-labeled a M , receptor-associated protein RAP and lactoferrin at2
physiologic temperatures by fibroblasts. Nickel completely inhibited the degradation of a M) over a wide range of2
 . ) 2qconcentrations 0.3–2.4 nM ; 50% inhibition for the degradation of 1.2 nM a M was observed at 0.5 mM Ni .2
Furthermore, nickel inhibited the binding, internalization and degradation of 125I-a M) in a dose- and time- dependent2
manner. In contrast, the degradation of several concentrations of 125I-RAP by fibroblasts was not affected by different
amounts of Ni2q for various times. Similarly, Ni2q did not inhibit the degradation of lactoferrin either before or after
treating the cells with heparitinase to remove cell-surface proteoglycans. The degradation of lactoferrin was, however,
inhibited by the RAP indicating that lactoferrin degradation was mediated by the LRP. These data suggest that Ni2q is a
specific inhibitor for the degradation of a M).2
Keywords: LDL receptor-related protein; Lipoprotein receptor-related protein; a -Macroglobulin; Nickel; Catabolism; Receptor associ-2
ated protein; Receptor; Lactoferrin
1. Introduction
Native a -macroglobulin, an abundant plasma pro-2
tease inhibitor, exists as a homotetramer. It interacts
Abbreviations: LDL, low density lipoprotein; VLDL, very
low density lipoprotein; a M), methylamine activated a -2 2
macroglobulin; RAP, receptor associated protein; EDTA, eth-
ylenediamine tetraacetic acid; TCA, trichloroacetic acid; MEF,
murine embryonic fibroblasts; DMEM, Dulbecco’s modified es-
sential medium
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with proteases and other proteins and forms irre-
versible complexes. Interaction between a -macro-2
globulin and proteases results in the hydrolysis of an
internal thiol-ester bond present in the a -macro-2
globulin, a conformational change in the molecule,
 w x.and entrapment of proteases for reviews, see 1–3 .
The conformational change in the a -macroglobulin2
exposes a hitherto buried receptor-binding site at its
carboxyl-end and in this state is called an activated
 ). )a -macroglobulin a M . The a M is cleared2 2 2
very rapidly from plasma by receptor-mediated endo-
 w x.cytosis for reviews, see 1–3 . The major receptor
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involved in the clearance of a M) is the low density2
 .lipoprotein LDL receptor related-proteinra -2
 .  wmacroglobulin receptor LRP for reviews, see 2–
x.9 . In addition to LRP, evidence has been presented
for the presence of a signaling receptor in
macrophages that interacts with a M) and increases2
w xintracellular calcium 10–12 .
The LRP is a multifunctional, cell-surface receptor
involved in the catabolism of proteases, prote-
aserprotease inhibitor complexes, lipoproteins and
 w x.other ligands for reviews, see 4–8 . It belongs to a
family of endocytic receptors structurally related to
the LDL receptor which includes the gp330rmegalin,
VLDL receptor, chicken vitellogenin receptor and
w xsome others 13–17 . These receptors are character-
ized by their ability to catabolize more than one
ligands which may be structurally and functionally
unrelated. Attempts to identify the a M) binding2
site on the LRP have been unsuccessful. For exam-
ple, different LRP fragments and minigene constructs
have been shown to bind RAP and other ligands but
) w xnot the a M 18,19 . These studies suggest that the2
a M) binding site is either different from the bind-2
 .ing site of receptor associated protein RAP and
other ligands or it is sensitive to biochemical and
molecular manipulations.
The RAP copurifies with LRP and acts as a chap-
w xerone during the biosynthesis of the receptor 20,21 .
It has been shown to inhibit the binding of all ligands
to the members of the LDL receptor family. Since,
w xthe LRP is essential for life 22 , inhibitors that
differentially inhibit the binding of different ligands
may be useful in controlling some physiologic func-
tions without affecting others. We have demonstrated
that nickel inhibits a M) binding to LRP at 48C but2
had no effect on the binding of RAP and Pseu-
w xdomonas exotoxin A to the receptor 23 . Nickel has
been shown to bind to purified, immobilized LRP at
w xtwo to three sites with a k of 0.04 mM 23 .d
The effect of nickel on a M) catabolism has not2
been studied under physiologic conditions. The ef-
fects observed at 48C can not be extrapolated to 378C.
It is well-known that several enzymes exhibit no or
significantly reduced activity at 48C compared to
378C. Similarly, several temperature sensitive muta-
tions result in loss of life at non-permissive tempera-
tures. Specifically, it has been demonstrated that
affinities for protein-protein interactions and protein-
metal interactions are different at different tempera-
tures. The effect of temperature on receptor-ligand
interaction has been well-documented. The affinity of
LDL to LDL receptor is decreased at 378C compared
w xto 48C 24 , whereas, the affinity of estradiol to
estrogen receptor is increased by 12-fold at higher
w xtemperatures 25 . Increase in temperature has also
been shown to result in decrease affinity of oxygen to
w xhemoglobin 26 . However, the effect of temperature
on metal-protein interactions has not been character-
ized in detail. It is, however, known that the binding
 .of Cu II to lysozyme, but not to ribonuclease, is
w xsignificantly decreased at 378C compared to 48C 27 .
Thus, in the present investigation, we studied the
effect of nickel on the cellular catabolism of different
ligands of LRP.
2. Materials and methods
2.1. Materials
Native a -macroglobulin, a generous gift from2
Drs. Maria Kounnas and Dudley Strickland of the
American Red Cross, was activated with meth-
w xylamine 23,28 . A plasmid expressing recombinant
GST-RAP was kindly provided by Dr. Joachim Herz
of the University of Texas, Dallas. RAP was purified
w x  .as described 28–30 . Lactoferrin catalog a L4894 ,
 . heparitinase a H8891 , dog serum albumin a
.A3184 and other chemicals were purchased from
 . 125Sigma Chemical Co. St. Louis, MO . Free I was
obtained from DuPontrNew England Nuclear
 .Wilmington, DE, catalog a NEZ-033A and used
w xfor radiolabeling of proteins 23,28,30,31 . Nickel
 .chloride catalog a N6136 was obtained from Sigma
and 100 mM stocks were prepared in 50 mM Tris,
containing 5 mM CaCl , pH 8.0. Fetal bovine serum2
and cell culture media were from Biofluids, MD, and
Bio-Whittaker, MD, respectively.
2.2. Cell cultures
 .A wild type murine embryonic fibroblast MEF
cell line and a derivative of this cell line that does not
express LRP were obtained from Dr. J. Herz Univer-
sity of Texas, Southwestern Medical Center, Dallas,
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.  .TX and cultured 378C, humidified airr5% CO in2
 .Dulbecco’s modified Eagle’s medium DMEM con-
taining 10% fetal bovine serum and penicillinrstrep-
 .tomycin Gibco BRL . Cells were plated at a density
of 100 000 cellsrwell in 24 well plates, allowed to
grow for 24 h at 378C and used for experiments.
Cells were 80–90% confluent at this time.
2.3. Binding, internalization and degradation of dif-
ferent ligands by cells
Cells were washed with DMEM containing peni-
cillinrstreptomycin and incubated in the same
medium for 60 min. To quantitate the amounts of
ligands degraded, cells were incubated with 125I-
) a M 1.2 nM or other indicated concentrations,2
. 125 specific activity 1000–2000 cpmrng , I-RAP 26
nM or other indicated concentrations, specific activity
. 125 1000–2000 cpmrng , or I-lactoferrin 12 mgrml,
.specific activity 1500–2000 in DMEM containing
15 mM Hepes, 4% pig serum albumin, pH 7.4, for 5
h at 378C. At the end of the experiments, cell culture
medium was collected into a tube containing tri-
 .chloroacetic acid TCA, final concentration of 10% ,
incubated on ice for 30 min, centrifuged and an
aliquot of the supernatant was counted. TCA soluble
counts represented degraded proteins. In all experi-
ments, ligand degradation was corrected for the
amount of TCA-soluble 125I present in control wells
with no cells. The free iodine represented less than
10% of the degraded ligand. To determine non-
specific degradation, 100-fold excess of unlabeled
ligands was added as indicated in different figure
legends. To measure cell surface binding and inter-
nalization of radiolabeled ligands, cells were washed
twice with DMEM and incubated with phosphate-
 .buffered saline pH 7.4 containing 50 mgrml trypsin
and 50 mgrml proteinase K and 5 mM EDTA for 15
w xmin at 48C 30–32 . The cell suspension was cen-
trifuged for 5 min at 48C, and the supernatant was
carefully transferred to another tube and counted;
these counts represented surface bound ligands at the
end of the experiment. The cell pellet was washed
twice, dissolved in 0.1 N NaOH, and counted; these
counts represented internalized ligands. Total protein
w xpresent in the cell pellet was determined 33 using
 .the Coomassie Plus reagent Pierce .
2.4. Heparitinase treatment of cells
MEF cultures were washed, and incubated for 5 h
at 378C with DMEM medium with or without hepar-
itinase final concentration, 4 Urml; 100= stock
was prepared in sterile saline immediately prior to
. w xuse as described by Ji and Mahley 34 . The medium
was removed, cells were washed three times and
incubated with DMEM containing 4 mgrml pig
serum albumin, 5 mM CaCl and different amounts2
of 125I-lactoferrin for 5 h at 378C. The amount of
lactoferrin degraded was measured as described
above.
3. Results
3.1. Effect of nickel on the degradation of a M ) by2
murine embryonic fibroblasts
Fig. 1 shows the effect of Ni2q on the binding,
internalization and degradation of different concentra-
tions of 125I-a M) at 378C. The degradation of2
a M) was linear up to 1.2 nM. The amount of2
) a M degraded at this concentration was f1002
.ngrmg cell protein similar to that observed by Will-
w xnow and Herz 35 . In the presence of 2 mM nickel,
however, MEF cultures were unable to degrade
a M). As shown in Fig. 1A, the specific degradation2
of a M) was inhibited by 90–100%. The internal-2
ization of radiolabeled a M) was also significantly2
 .inhibited by nickel Fig. 1B . The inhibition of inter-
nalization and degradation was probably due to the
) inhibition of a M binding to cells by nickel Fig.2
. )1C . MEF cells bound significant amounts of a M .2
But, in the presence of nickel, no specific binding
 .could be observed Fig. 1C ; since the values were
close to zero, the line representing the effect of nickel
is not visible. These studies suggest that nickel in-
hibits the binding, internalization and degradation of
125I-a M).2
To study the dose response effect of nickel on
a M) degradation, cells were incubated with radio-2
labeled a M) with various concentrations of Ni2q2
 . 125Fig. 2 . Nickel inhibited the degradation of I-
)  .a M at all concentrations Fig. 2A . The concentra-2
tion of Ni2q required for 50% inhibition was f0.5
 . )mM Fig. 2A . The amount of a M internalized2
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Fig. 1. Effect of nickel on the binding, internalization, and degradation of different concentrations of 125I-a M). Confluent MEF cultures2
were incubated with different concentrations of 125I-a M) in the absence or presence of 100-fold excess of unlabeled a M) with or2 2
without 2 mM nickel. After incubating for 5 h at 378C, the medium was removed, subjected to TCA-precipitation, and the amount of
125I-a M) degraded was determined as described in Section 2. To determine the surface binding and internalization, cells were washed2
 .  .with DMEM, and treated with trypsin-EDTA, and proteinase K as described in Section 2. Specific degradation A , internalization B ,
 .and binding C in the presence and absence of nickel are presented as line graphs. Each data point represents the mean of triplicate
determinations"S.D.
and bound was significantly lower than the amount of
)  .a M degraded compare Fig. 2A with 2B and 2C2
and was inhibited by increasing concentrations of
 .nickel Fig. 2B and 2C . These studies indicate that
nickel inhibits a M) catabolism in a dose-dependent2
manner.
To further characterize the effect of Ni2q on cellu-
lar catabolism of a M), we studied the effect of2
Fig. 2. Inhibition of the binding, internalization and degradation of 125I-a M) by different concentrations of nickel. Fibroblasts were2
incubated in triplicate with 1.2 nM 125I-a M) in the presence and absence of different concentrations of nickel as indicated. After 5 h of2
 .  .  . )incubation at 378C, the specific degradation A , internalization B and binding C of a M was determined as described in Fig. 1 and2
Section 2. Each value represents the mean"S.D., ns3.
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Fig. 3. Effect of nickel on the degradation of 125I-a M) with time. Degradation assays were performed as described in Fig. 1 and2
125 )  .Section 2. Media containing I-a M 1.2 nM was added to MEF cultures in 24 well plate and incubated at 378C for the indicated2
time intervals with or without 2 mM nickel. Non-specific degradation was measured in the presence of 100-fold excess of unlabeled
a M). A, B and C represent total, non-specific and specific degradation, respectively. Each value represents a mean of triplicate2
determinations and the error bars represent S.D.
 .nickel with time Fig. 3 . Total and specific degrada-
125 ) tion of I-a M increased with time Fig. 3A and2
.3C . The non-specific degradation was less than 25%
 .of the total at different times Fig. 3B . The time
dependent increased degradation of a M) was com-2
 .pletely inhibited in the presence of nickel Fig. 3A .
These studies indicate that nickel inhibits a M)2
degradation and that the effect of nickel persists for
long time.
Recently, evidence for the binding of a M) to a2
w xsignaling receptor has been presented 10,11 . In
contrast to the binding of a M) to LRP, its binding2
to the signaling receptor is not inhibited by RAP. To
show that Ni2q is not inhibiting the binding of
Fig. 4. Effect of nickel on the catabolism of 125I-RAP. Mouse embryonic fibroblasts were incubated for 5 h with different concentrations
125  .of I-RAP in the absence or presence of nickel 2 mM . To determine non-specific binding, internalization and degradation, cells were
incubated with the same amounts of radiolabeled RAP in the presence of 100-fold excess of unlabeled RAP. The non-specific binding
was less than 25% of the total binding. Degradation assays were performed at 378C as described in Fig. 1 and Section 2. A, B and C
represent specific degradation, internalization and binding, respectively. Data are the mean"S.D. of triplicate determinations.
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Fig. 5. Effect of different concentrations of nickel on the degradation, internalization and binding of 125I-RAP. Assay conditions were as
in Fig. 4. Cells were incubated in triplicate with media containing 26 nM 125I-RAP and different indicated concentrations of Ni2q at 378C
for 5 h. A, B and C represent specific degradation, internalization and binding, respectively. Each data point represents mean"S.D.
a M) to the signaling receptor, we performed com-2
petition experiments using RAP. RAP inhibited the
) a M degradation in a dose-dependent manner data2
. )not shown , suggesting that a M was being de-2
graded primarily by the LRP and Ni2q inhibited this
degradation. Recently, Howard et al. have also shown
that a M) is mainly degraded by LRP and not by2
w xthe signaling receptor 12 . The importance of the
binding of a M) to LRP was demonstrated further2
using fibroblasts that were deficient in LRP. These
fibroblasts did not catabolize any significant amounts
) w xof a M as has been previously reported 35 . Thus,2
a M) is primarily degraded by a LRP-dependent2
endocytic pathway.
Fig. 6. Effect of nickel on the degradation of 125I-RAP with time. Cells were incubated at 378C with 26 nM 125I-RAP in the presence or
absence of 2 mM nickel. Non-specific degradation was measured in the presence of 100-fold excess of unlabeled RAP. At specified time
intervals, media were collected and subjected to TCA precipitation and degradation of 125I-RAP was determined as described in Section
2. A, B and C represent total, non-specific and specific degradation, respectively. Each value in the graph indicates mean of triplicate
determinations and error bars represent S.D.
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3.2. Effect of Ni2q on the degradation of RAP
To investigate the specificity of the inhibitory
action of the Ni2q, we studied its effect on the
degradation of two different ligands; RAP competes
) . for a M binding to LRP and lactoferrin does not2
) .compete for a M binding . The degradation, inter-2
nalization, and binding of RAP was linear with in-
creasing concentrations of added radiolabeled RAP
 .Fig. 4 . Inclusion of nickel in parallel cultures had
 .no effect on these processes Fig. 4 . Note that under
similar conditions, nickel completely inhibited the
) degradation of a M compare Fig. 4A with Fig.2
.1A . Next, we studied the effect of different concen-
 .trations of nickel on the catabolism of RAP Fig. 5 .
At all concentrations used, nickel had no inhibitory
 .effect on the degradation of RAP Fig. 5A . Note that
1.6 mM nickel inhibited about 90% of the a M)2
degradation but had no effect on RAP degradation
 .compare Fig. 2 with Fig. 5 . To examine if higher
concentrations of nickel would inhibit RAP degrada-
tion, we used up to 6.4 mM nickel with no effect on
 .RAP degradation data not shown . These studies
 .suggest that nickel 0.2 to 6.4 mM had no significant
inhibitory effect on RAP catabolism. Furthermore,
we studied the effect of Ni2q on the time-course of
RAP degradation. The total degradation of RAP in-
creased with time and was in general greater in the
 .presence of nickel Fig. 6A . This was mainly due to
increased non-specific degradation of RAP in the
 .presence of nickel Fig. 6B . Nonetheless, non-
specific degradation was less than 25% of the total
degradation. The specific degradation of RAP was
similar in cells incubated with or without nickel Fig.
.6C . Only at 8 h, f20% inhibition in RAP degrada-
tion was observed. Note that under similar condi-
tions, a M) degradation was completely inhibited2
 .compare Fig. 6C with Fig. 3C . These studies indi-
cate that Ni2q does not inhibit the catabolism of RAP
but specifically inhibits a M) catabolism.2
3.3. Effect of Ni2q on the degradation of lactoferrin
by LRP
To investigate further the specificity of Ni2q ef-
fect, we used another ligand of LRP, lactoferrin.
Cells were incubated with 125I-lactoferrin at 378C for
2q  .5 h, with or without Ni Fig. 7A . We studied the
degradation of 125I-a M) in parallel. Nickel did not2
inhibit the degradation of lactoferrin but inhibited the
)  .degradation of a M Fig. 7A . Lactoferrin is known2
w xto bind to proteoglycans in addition to the LRP 34 .
Consideration was given to the possibility that nickel
did not affect lactoferrin degradation because the
majority of the lactoferrin was binding to proteogly-
cans and nickel does not affect this binding. Thus, to
study the effect of nickel on the LRP-mediated degra-
125 125 Fig. 7. Effect of nickel on I-lactoferrin degradation. A: Fibroblasts were incubated with medium containing either I-lactoferrin 12
. 125 )  .  .mgrml or I-a M 1.2 nM in the presence or absence of nickel 2 mM . The amount of degraded ligands was determined as2
 .described in Section 2. B: Cells were treated with heparitinase 4 Urml, 5 h, 378C as described in Section 2, washed and incubated with
 .  .  .radiolabeled lactoferrin in the presence of medium alone control , medium containing nickel chloride 2 mM or RAP 60 mgrml . After
5 h, the amount of degraded lactoferrin was measured as described in Section 2.
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dation of lactoferrin in the absence of cell-surface
proteoglycans, cells were pretreated with heparitinase
w x34 . Heparitinase treatment of cells decreased lacto-
 .ferrin degradation by 50% Fig. 7B compared to
 .non-treated cells compare with Fig. 7A . This is in
agreement with other studies describing decreased
degradation of lactoferrin after heparitinase treatment
w x34 . Next, degradation of lactoferrin was studied in
the presence of nickel in heparitinase-treated cells
 .Fig. 7B . Again, nickel had no inhibitory effect on
the degradation of lactoferrin. To confirm that lacto-
ferrin was being degraded by LRP-mediated endo-
cytic process, its degradation was studied in the
presence of unlabeled RAP. RAP inhibited greater
than 70% of the lactoferrin degradation in hepariti-
nase-treated cells indicating that majority of the
lactoferrin was degraded by LRP-mediated endocyto-
w xsis as has been described by others 34,36 . The
residual binding may indicate presence of additional
binding sites for lactoferrin or an incomplete compe-
tition by the RAP. These studies suggested that the
catabolism of lactoferrin was not inhibited by nickel.
4. Discussion
In the present study, we demonstrated that Ni2q
specifically inhibits the binding, internalization and
degradation of a M) by fibroblasts at 378C. It did2
not inhibit the catabolism of RAP and lactoferrin
indicating that nickel is a very specific inhibitor for
) w xa M catabolism. Previously 23 , we have shown2
that nickel inhibits the binding of a M) to LRP but2
had no effect on the binding of RAP or Pseudomonas
exotoxin A. The inhibitory effect of Ni2q on the
binding of a M) to cells at 48C was not due to its2
interaction with a M) but was due to its interaction2
with LRP. Thus, it appears that nickel possibly binds
to LRP and inhibits a M) catabolism by cells.2
The inhibition of a M) degradation by nickel2
was surprising because nickel has low affinity for the
w x )LRP 23 . Furthermore, it was known that a M2
binds with very high affinity to LRP at 378C and is
w xcleared very rapidly from circulation 1–3 . The ob-
served inhibition indicates that nickel acts as a potent
antagonist probably because two to three molecules
w xof nickel bind to the receptor 23 and this binding
causes conformational change in LRP resulting in
significantly decreased affinity towards a M). More2
experiments are required to understand the mecha-
nism of inhibition by nickel.
The catabolism of a M) has been shown to be2
inhibited after its covalent modification with cis-di-
w xchlorodiammineplatinum 12,37,38 . This modifica-
tion, which occurs away from the receptor binding
site, has no significant effect on its binding to LRP.
The modification, however, decreases the dissocia-
tion of a M) from the receptor in the endocytic2
w xvesicles 12 . In contrast, nickel appears to interact
with the LRP and inhibits the binding of a M) to2
w x )the receptor 23 . a M catabolism is also inhibited2
by RAP, a universal antagonist that inhibits the
catabolism of all the ligands of the LDL receptor
family. In contrast to RAP, nickel appears to be a
very specific inhibitor for the degradation of a M).2
Although unlikely, consideration was given to the
possibility that a M) was catabolized by a LRP-in-2
dependent pathway that is sensitive to nickel. This
possibility was considered unlikely due to several
reasons. a M) binds only to LRP and does not bind2
to the LDL receptor, VLDL receptor or
w xgp330rmegalin 39–41 . Zero or significantly re-
duced expression of LRP has been shown to result in
) w xdecreased catabolism of a M in fibroblasts 352
w xand in transgenic mice 20 . In contrast, deletion of
the LDL receptor or VLDL receptor had no signifi-
) w xcant effect on a M catabolism 20,42,43 . In the2
present investigation, we could not measure any sig-
nificant degradation of a M) by the LRP-deficient2
w xfibroblasts in agreement with other studies 35 . Thus,
the most of the a M) catabolism was mediated by2
the LRP.
The degradation of RAP and lactoferrin was not
inhibited by nickel. The binding affinity of RAP and
lactoferrin to the LDL receptor is significantly less
w xthan LRP 43–45 indicating that the LDL receptor is
not the major receptor involved in the catabolism of
RAP and lactoferrin in these cells. Several studies
have established that LRP plays a very important role
in the catabolism of RAP and lactoferrin
w x29,34,36,46–48 . A more likely explanation for the
lack of inhibition of RAP and lactoferrin degradation
is that nickel binds to a site some distance away from
the binding site of these ligands and thus does not
interfere with their catabolism.
The LDL receptor family is characterized by the
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fact that each receptor recognizes more than one
ligand and usually each ligand is recognized by more
than one receptor. For example, ligands RAP, uPA-
PAI-1, lipoprotein lipase and lactoferrin are catabo-
lized by the LRP, gp330rmegalin, chicken vitelloge-
wnin receptor and VLDL receptor 29,32,36,40,46,49–
x )54 . The only possible exception is that a M is2
w xrecognized only by the LRP 39–41,45 . There are
conflicting reports concerning the binding of a M)2
to the VLDL receptor probably due to species differ-
w x )ences 39,40,55 . This indicates that the a M bind-2
ing site is unique and is only present in the LRP.
In summary, we have demonstrated that nickel is a
very specific inhibitor for the catabolism of a M). It2
had no effect on the cellular catabolism of RAP and
lactoferrin. Although the physiologic significance of
this observation is not obvious, the specificity and
potency of its action suggest that nickel may be a
useful and specific tool to identify the binding site of
a M) to the LRP.2
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